Research Topics
| M ButiSummaryAffiliation: Hospital Universitari Vall d'Hebron Country: Spain Publications
| Collaborators
|
Detail Information
Publications
Cost effectiveness of first-line oral antiviral therapies for chronic hepatitis B : a systematic reviewMaria Buti
Servicio de Hepatologia, Hospital General Universitario Valle de Hebron, Paseo Valle de Hebron 119, 08035, Barcelona, Spain
Pharmacoeconomics 31:63-75. 2013..Chronic hepatitis B is a common, progressive disease, particularly when viral replication is detected. Oral antivirals can suppress viral replication and prevent or delay the development of cirrhosis and liver-related complications...- Tenofovir disoproxil fumarate in the treatment of chronic hepatitis BMaria Buti
CIBERehd, Instituto Carlos III, Madrid, Spain
Expert Rev Gastroenterol Hepatol 6:413-21. 2012..In addition, studies including patients that have been previously treated with lamivudine or adefovir are discussed... - [Quantification of hepatitis B virus HBsAg: clinical implications]Maria Buti
Servicio de Hepatologia, Hospital Universitario Vall d Hebron, Barcelona, Spain
Med Clin (Barc) 138:483-8. 2012..The role of the quantification of HBsAg in the treatment with nucleoside analogues is still not well understood and requires further studies... - Efficacy and safety of entecavir in clinical practice in treatment-naive Caucasian chronic hepatitis B patientsMaria Buti
CIBER on Liver and Digestive Diseases, Hospital Vall d Hebron, corrected Barcelona, Spain
Eur J Gastroenterol Hepatol 24:535-42. 2012..Entecavir is an effective treatment for chronic hepatitis B. However, data from clinical practice are limited, especially in hepatitis B e antigen (HBeAg)-positive patients... - [New agents for the treatment of hepatitis C]Maria Buti
Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas CIBERehd, Instituto de Salud Carlos III, Espana
Enferm Infecc Microbiol Clin 30:147-50. 2012..Both increase rates of SVR in naïve and in previously treated patients with the advantage that in some cases therapy can be shortened. However, these drugs have new side effects such as a rash and an increase in the rate of anaemia... 
Paracetamol in therapeutic dosages and acute liver injury: causality assessment in a prospective case seriesMònica Sabaté
Fundacio Institut Catala de Farmacologia, Universitat Autonoma de Barcelona, Hospital Universitari Vall d Hebron, Barcelona, Spain
BMC Gastroenterol 11:80. 2011..The aim is to describe the characteristics of patients admitted to hospital with jaundice who had previous exposure to therapeutic doses of paracetamol. An assessment of the causality role of paracetamol was performed in each case...- Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic responseMaria Buti
Liver Unit, Valle d Hebron Ciberehd University Hospital, and Biomedical Research Center Network in the Area of Hepatic and Digestive Disorders of the Carlos III Health Institute, Barcelona, Spain
Hepatology 52:1201-7. 2010..CONCLUSION: These data suggest that 48 weeks of therapy with PEG-IFN alfa-2b plus RBV (800-1,400 mg/day) should remain a standard-of-care treatment for treatment-naïve G1 slow responders... 
[Current and future applications of viral clearance kinetics in the treatment of hepatitis C]M Buti
, Hospital General Universitari Vall d'Hebron, Paseo Vall d'Hebron, 119, 08035 Barcelona,
Gastroenterol Hepatol 27:24-9. 2004- Sporadic cases of acute autochthonous hepatitis E in SpainMaria Buti
Liver Unit, Hospital General Universitario Valle Hebron, Paseo Valle de Hebron 119, 08035 Barcelona, Spain
J Hepatol 41:126-31. 2004..In industrialized countries hepatitis E virus (HEV) infection is rare and its diagnosis is difficult because the utility of available tests is not well established... - Clinical outcome of acute and chronic hepatitis delta over time: a long-term follow-up studyM Buti
CIBERehd, Instituto de Salud Carlos III, Ministerio de Ciencia e Innovacion, Barcelona, Spain
J Viral Hepat 18:434-42. 2011..Currently, patients with chronic HDV disease are older, and factors associated with worse prognosis include the presence of cirrhosis and age at the time of diagnosis... - Hepatitis B virus genome variability and disease progression: the impact of pre-core mutants and HBV genotypesMaria Buti
Liner Unit, Hospital General Universitari Pall d Hebron, Barcelona, Spain
J Clin Virol 34:S79-82. 2005..Analyses of both naturally occurring viral variants and in vitro mutagenesis studies have identified some mutations that have a role in viral latency, pathogenesis of liver disease, immune escape, and resistance to antiviral therapy... - Cost-effectiveness analysis of lamivudine and adefovir dipivoxil in the treatment of patients with HBeAg-negative chronic hepatitis BM Buti
Department of Hepatology, Hospital Vall d Hebron, Barcelona, Spain
Aliment Pharmacol Ther 23:409-19. 2006..To estimate the cost-effectiveness over a 4-year duration of lamivudine and adefovir dipivoxil for patients with hepatitis B 'e' antigen-negative chronic hepatitis B... - Drugs in development for hepatitis BMaria Buti
Liver Unit, Hospital General Universitari Vall d Hebron, Barcelona, Spain
Drugs 65:1451-60. 2005.... - Financial impact of two different ways of evaluating early virological response to peginterferon-alpha-2b plus ribavirin therapy in treatment-naive patients with chronic hepatitis C virus genotype 1Maria Buti
Department of Hepatology, Hospital Vall d Hebron, Barcelona, Spain
Pharmacoeconomics 23:1043-55. 2005..The monitoring of early virological response (EVR) is therefore an important tool for quickly identifying non-responders, permitting therapy discontinuation and avoiding adverse effects and costs... - Hepatitis C virus Core Antigen as a predictor of non-response in genotype 1 chronic hepatitis C patients treated with peginterferon alpha-2b plus ribavirinMaria Buti
Servicio de Hepatologia, Hospital General Universitario Valle de Hebron, Barcelona, Spain
J Hepatol 40:527-32. 2004..We examined the usefulness of measuring total HCV Core Ag in early treatment with peginterferon alpha-2b and ribavirin in genotype 1 patients in the prediction of response and compared the results with those from HCV RNA quantification... - 1990-2010: two decades of interferon-based therapyMaria Buti
Liver Unit, Hospital General, Universitario Valle Hebron, Paseo Valle Hebron 119, Barcelona 08035, Spain
Clin Liver Dis 15:473-82. 2011..Even with the development of new protease inhibitors, it is likely that interferon will remain an essential component of hepatitis C treatment... - Hepatitis B and C virus resistance to antiviral therapies--EASL-AASLD-APASL-ALEH-IASL conferenceMaria Buti
Hospital Vall d'Hebron/CIBER-EHD, Liver Unit, Paseo Valle de Hebron 119, Barcelona 0803, Spain
IDrugs 11:239-41. 2008 - [Telbivudine in the treatment of the chronic B hepatitis]María Asunción Butí
Servicio de Hepatologia, Hospital General Universitario Vall d Hebron, Barcelona, Spain
Gastroenterol Hepatol 31:258-63. 2008 - [Nucleoside and nucleotide analogs in the treatment of chronic hepatitis B]Maria Buti
Servicio de Hepatología y Medicina Interna, Hospital General Universitario Vall d Hebron, CIBER del Instituto de Salud Carlos II, Barcelona, Espana
Enferm Infecc Microbiol Clin 26:32-8. 2008..In cases of resistance to one of these drugs, combined treatment is advised... - [Therapy of chronic hepatitis B]Maria Buti
Hospital General Universitario Vall d Hebrón de Barcelona, Barcelona, Espana
Acta Gastroenterol Latinoam 38:291-7. 2008..The challenge are to prevent the emergence of HBV drug resistance and to achieve complete and persistent HBV replication in order to avoid the progression of the liver disease and the development of HBV related complications... - Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis CMaria Buti
Department of Hepatology, Hospital Vall d Hebron, Barcelona, Spain
J Hepatol 42:639-45. 2005..Our aim was to estimate the future morbidity, mortality and costs of chronic HCV infection in a cohort of patients infected by HCV and to evaluate the impact of HCV therapy... - Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patientsM Buti
Liver Unit and Biochemistry Department, Hospital Universitario Vall d Hebron and CIBER EHD, Barcelona, Spain
J Hepatol 47:366-72. 2007..To determine the factors associated with virological response (VR), HBeAg loss or the emergence of adefovir (ADV)-related mutations in ADV-treated chronic hepatitis B (CHB) patients with lamivudine (LAM) resistance... - Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis BMaria Buti
Servicio de Hepatologi a, Hospital Vall d Hebrón and Ciber ehd del Instituto Carlos III, Barcelona, Spain
J Hepatol 51:640-6. 2009..The aim of this study was to estimate the cost-effectiveness of the oral antiviral treatments lamivudine, adefovir, telbivudine, entecavir and tenofovir, in patients with CHB... - Evaluating the cost of sustained virologic response in naïve chronic hepatitis C patients treated à la carteM Buti
Department of Hepatology, Hospital Vall d Hebron, and CiBER de Enfermedades Hepaticas y Digestivas del Instituto de Salud Carlos III, Barcelona, Spain
Aliment Pharmacol Ther 26:705-16. 2007..There is a tendency to individualize treatment in chronic hepatitis C patients depending on viral load and rapid clearance of HCV-RNA... - Quality of life and cost-effectiveness of anti-HCV therapy in HIV-infected patientsMaria Buti
Liver Unit, Hospital General Universitario Valle de Hebron, Paseo Valle hebron 117, Barcelona 08035, Spain
J Hepatol 44:S60-4. 2006..Currently, the literature does not provide adequate information on the effect of HCV infection on the quality of life of HIV-HCV co-infected patients or the most cost-effective HCV therapy... - Role of hepatitis B, C, and D viruses in dual and triple infection: influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative interferenceR Jardi
Department of Biochemistry, Hospital Universitario Vall d Hebron, Barcelona, Spain
Hepatology 34:404-10. 2001..The reciprocal inhibition of viral replication seemed to be little influenced by the inherent genomic factors studied... - Quantitative hepatitis B virus DNA testing for the early prediction of the maintenance of response during lamivudine therapy in patients with chronic hepatitis BM Buti
Unidad de Hepatologia, Hospital General Universitario Valle de Hebron, Paseo Valle Hebron s n, Barcelona 08035, Spain
J Infect Dis 183:1277-80. 2001..Therefore, quantitative HBV DNA testing is very useful in deciding whether to continue therapy, because of the low likelihood of response in patients who remain HBV DNA positive at month 3 of treatment... - Hepatitis B virus genotypes and G1896A precore mutation in 486 Spanish patients with acute and chronic HBV infectionF Rodriguez-Frias
Department of Biochemistry, Hospital Universitario Vall d'Hebron, Barcelona, Spain
J Viral Hepat 13:343-50. 2006..The unequal prevalence of genotypes between acute and chronic infection suggests that genotype A is associated with a higher tendency to cause chronic infection... - Hepatitis B virus polymerase variants associated with entecavir drug resistance in treatment-naive patientsR Jardi
Department of Biochemistry, Hospital Universitario Vall d Hebron, Barcelona, Spain
J Viral Hepat 14:835-40. 2007..This fact, as well as the emergence of ETV-resistant variants during lamivudine treatment, should be kept in mind when selecting candidates for ETV therapy... - Rapid detection of lamivudine-resistant hepatitis B virus polymerase gene variantsR Jardi
Department of Biochemistry, Hospital Universitario Valle Hebron, Paseo Valle Hebron s n, Barcelona, Spain
J Virol Methods 83:181-7. 1999..Since it is a rapid low-cost technique, PCR- RFLP is suitable for large-scale screening of these polymorphisms in clinical samples... - Cost-effectiveness of combination therapy for naive patients with chronic hepatitis CM Buti
Department of Hepatology, Hospital Vall d Hebron, Barcelona, Spain
J Hepatol 33:651-8. 2000..The objective of this study was to determine if the incremental sustained response rate of combination therapy is sufficient to outweigh its extra cost... - Study on the efficacy and safety of adefovir dipivoxil treatment in post-liver transplant patients with hepatitis B virus infection and lamivudine-resistant hepatitis B virusR Barcena
Hospital Ramon y Cajal, Madrid, Spain
Transplant Proc 37:3960-2. 2005.... - Main mutations in the hepatitis B virus basic core promoter (A1762T/G1764A) before HBeAg loss are markers that identify patients who will require long-term treatmentD Tabernero
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Barcelona, Spain
Aliment Pharmacol Ther 32:97-104. 2010..Some patients continue to have detectable HBV-DNA levels with liver disease progression after hepatitis B e antigen (HBeAg) loss. It is important to identify these patients, candidates for long-term treatment... - Quantitative detection of hepatitis B virus DNA in serum by a new rapid real-time fluorescence PCR assayR Jardi
Department of Biochemistry, Hospital Universitario Vall d Hebron, Barcelona, Spain
J Viral Hepat 8:465-71. 2001..The assay is automatic except for DNA extraction and the running time is only 70 min. The LightCycler real-time PCR is useful for identifying different states of HBV infection and for evaluating the efficacy of viral therapy... - Changes in different regions of hepatitis B virus gene in hepatitis B 'e' antigen-negative patients with chronic hepatitis B: the effect of long-term lamivudine therapyM Buti
Liver Unit, Servicio de Hepatologia, Hospital General Universitario Valle de Hebron, Barcelona, Spain
Aliment Pharmacol Ther 21:1349-56. 2005..Lamivudine therapy for chronic hepatitis B has been associated with changes in different regions of the hepatitis B virus nucleotide sequence... - Two years of lamivudine therapy in anti-HBe-positive patients with chronic hepatitis BM Buti
Unidad de Hepatologia, Hospital General Universitario Valle de Hebron, Barcelona, Spain; Glaxo Wellcome, Madrid, Spain
J Viral Hepat 8:270-5. 2001..However, its efficacy tends to decrease overtime and it is associated with an increase in YMDD variants, even in some cases, of complete response... - A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis CM Buti
Department of Hepatology, Hospital Vall d Hebron, Barcelona, Spain
Aliment Pharmacol Ther 17:687-94. 2003..To estimate the cost-effectiveness of therapy and analyse the effect of therapy compliance in naive patients with chronic hepatitis C... - HIV, HEV and cirrhosis: evidence of a possible link from eastern SpainR Jardi
Department of Biochemistry, Vall d Hebron Hospital, University Autonoma of Barcelona, Barcelona, Spain
HIV Med 13:379-83. 2012..The aim of the study was to assess the seroprevalence of hepatitis E virus (HEV) infection in an HIV-infected population, as determined by HEV immunoglobulin G (IgG) antibodies (anti-HEV)... - High-Dose interferon-alpha2b plus ribavirin for retreatment of interferon-nonresponsive patients infected with genotype 1 hepatitis C virusM Buti
Liver Unit, Hospital General Universitari Vall d'Hebron, Barcelona, Spain
Dig Dis Sci 46:2396-400. 2001..Retreatment with an initial high-dose IFN-alpha2b plus ribavirin significantly reduces viral load in genotype 1-infected, interferon-nonresponsive patients... - Peginterferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patientsM Crespo
Infectious Diseases Department, Hospital Universitari Vall d Hebron, Barcelona, Spain
J Viral Hepat 14:228-38. 2007..Frequent monitoring of virological response may be very helpful to optimize treatment compliance, to tailor treatment duration and to minimize side effects... - Quantitative longitudinal evaluations of hepatitis delta virus RNA and hepatitis B virus DNA shows a dynamic, complex replicative profile in chronic hepatitis B and DMelanie Schaper
Department of Biochemistry, Hospital Universitario Vall d Hebron, Barcelona 08035, Spain
J Hepatol 52:658-64. 2010..This study presents a real-time reverse-transcription PCR (rt-RT-PCR) assay for hepatitis delta virus (HDV) RNA quantification, designed to clarify the interplay between HDV and hepatitis B virus (HBV) in chronic infection... - Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirinMaria Buti
Liver Unit, Hospital General Universitari Vall d Hebron, Barcelona, Spain
Hepatology 35:930-6. 2002..Higher doses of peginterferon alfa-2b also accelerate viral clearance... - Redetection of HBV lamivudine-resistant mutations in a patient under entecavir therapy, who had been treated sequentially with nucleos(t)ide analoguesFrancisco Rodriguez Frias
Department of Biochemistry, Hospital Universitario Vall d Hebron, Barcelona, Spain
J Med Virol 79:1671-3. 2007..Despite the presence of these variants, the patient has had a complete virological response... - [Study of HLA-II antigens in chronic hepatitis C and B and in acute hepatitis B]M Cotrina
Servicio de Hepatologia, Hospital General Universitario Vall d Hebron, Barcelona
Gastroenterol Hepatol 20:115-8. 1997..The use of PCR techniques which discriminate between the different alleles of the HLA antigens may provide better knowledge of the immune response... - Current trends in chronic hepatitis B management: results of a questionnaireIñigo Les
Liver Unit, Hospital General Universitario Vall d Hebron and CIBER EHD, Barcelona, Spain
Eur J Gastroenterol Hepatol 21:1177-83. 2009..Aim of this study was to analyze general knowledge, therapeutic and diagnostic trends of physicians treating CHB in Spain... - Mutations in the basic core promoter region of hepatitis B virus. Relationship with precore variants and HBV genotypes in a Spanish population of HBV carriersRosendo Jardi
Department of Biochemistry, Hospital Universitario Vall d Hebron, Paseo Vall d Hebron 119 129, Barcelona 08035, Spain
J Hepatol 40:507-14. 2004..To determine the prevalence and significance of hepatitis B virus (HBV) basic core promoter (BCP) mutations and to establish their relationship with precore (preC) mutations, HBV genotypes and HBV-DNA levels... - [Adefovir dipivoxil compassionate use program in Spain: efficacy and resistance analysis]Maria Buti
Servicio de Hepatologia, Hospital Universitari Vall d Hebron, Barcelona, Espana
Med Clin (Barc) 129:566-70. 2007..The aim of this study was to evaluate the efficacy, safety and resistance of adefovir dipivoxil in patients with chronic hepatitis B refractory to treatment with lamivudine... - Severe anaemia related to oseltamivir during treatment of chronic hepatitis C: a new drug interaction?M Simón-Talero
Liver Unit, Hospital Universitari Vall d Hebron, Department of Medicine, Universitat Autonoma de Barcelona, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Instituto de Salud Carlos III, Barcelona, Spain
J Viral Hepat 19:14-7. 2012..The adverse events related to ribavirin and drug-drug interactions during therapy for hepatitis C are discussed... - Current therapies for chronic hepatitis BMaria Buti
Liver Unit, Hospital General Universitari Vall d'Hebron, Barcelona, Spain
Ann Hepatol 2:108-12. 2003 - Usefulness of dried blood samples for quantification and molecular characterization of HBV-DNARosendo Jardi
Department of Biochemistry, Hospital Universitario Vall d Hebron, Barcelona, Spain
Hepatology 40:133-9. 2004..In conclusion, the DBS sample is useful for HBV DNA quantification, genotyping, and detection of precore mutant and YMDD variants. All four determinations can be completed with a single drop of dried blood... - Simultaneous quantification and genotyping of hepatitis B virus for genotypes A to G by real-time PCR and two-step melting curve analysisWen-Chun Liu
Institute of Basic Medical Sciences, Department of Medicine, National Cheng Kung University, Tainan City 704, Taiwan, Republic of China, and Liver Unit, Hospital General Universitari Vall d'Hebron, Barcelona, Spain
J Clin Microbiol 44:4491-7. 2006..3% of 441 samples were accurately genotyped by the current assay. The method should be useful for genotyping and quantification of HBV DNA in areas where all genotypes exist... - Prevalence of hepatitis E virus infection in children in the northeast of SpainMaria Buti
Liver Unit, Biochemistry Departament, Hospital Universitario Valle Hebron and CIBER EHD of Instituto Carlos III, Passeig Vall d Hebron 119 121, 08035 Barcelona, Spain
Clin Vaccine Immunol 15:732-4. 2008..IgG anti-HEV antibodies were detected in 57 (4.6%) of the 1,249 samples analyzed, suggesting that some children are exposed to HEV in early childhood... - Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3/HIV co-infected patientsManuel Crespo
Infectious Diseases Department, Spain
AIDS 21:477-81. 2007..To investigate the utility of a week-4 virological response for sustained response prediction in hepatitis C virus (HCV) genotype 3/HIV-co-infected patients treated with interferon and ribavirin for 24 weeks... - Entecavir, FTC, L-FMAU, LdT and othersMaria Buti
Liver Unit, Hospital General Universitari Vall d Hebron, Paseo Valle de Hebron 119, Barcelona 08035, Spain
J Hepatol 39:S139-42. 2003..Currently, the drugs most likely to fulfill these criteria are the nucleoside analogs... - Successful use of entecavir for a severe case of reactivation of hepatitis B virus following polychemotherapy containing rituximabMayra J Sanchez
Hospital Vall d Hebron, Liver Unit, CIBERehd Institute Carlos III, Paseo de Vall d Hebron, 08035 Barcelona, Spain
J Hepatol 51:1091-6. 2009..Patients with severe reactivation often have a fatal outcome despite treatment with lamivudine. The use of entecavir has not been reported in patients with severe HBV reactivation... - De novo nephrotic syndrome following pegylated interferon alfa 2b/ribavirin therapy for chronic hepatitis C infectionJose L Tovar
Servicio de Nefrologia, Hospital General Universitario Valle de Hebron, Barcelona 08035, Spain
Int Urol Nephrol 40:539-41. 2008..The patient exhibited a total remission when the antiviral treatment was discontinued... - Analysis of hepatitis B genotype changes in chronic hepatitis B infection: Influence of antiviral therapyRosendo Jardi
Department of Biochemistry, Hospital General Universitario Vall d Hebron, Paseo Valle Hebron s n, Servicio de Bioquimica, Barcelona 08035, Spain
J Hepatol 49:695-701. 2008..The frequency of mixed hepatitis B virus (HBV) genotypes in chronic HBV (CHB) and genotype changes during natural disease evolution and as a result of antiviral therapy were investigated... - Adefovir for chronic hepatitis B treatment: identification of virological markers linked to therapy responseFrancisco Rodriguez-Frias
Department of Biochemistry, Hospital Universitario Vall d Hebron, Barcelona, Spain
Antivir Ther 13:991-9. 2008..Virological characteristics useful for predicting response have not been clearly elucidated. We determined pretreatment virological markers to predict non-response and possible emergence of new variants during therapy... - Use of the novel INNO-LiPA line probe assay for detection of hepatitis B virus variants that confer resistance to entecavir therapyRosendo Jardi
Departments of Biochemistry, Hospital Universitario Vall d Hebron, Barcelona, Spain
J Clin Microbiol 47:485-8. 2009..The INNO-LiPA DR assay is a highly sensitive assay that is easily applicable for the detection and monitoring of entecavir resistance-conferring mutations and is more sensitive than sequencing for the detection of mixed sequences... - Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantationLluis Castells
Liver Unit, Department of Biochemestry, Hospital General Vall d Hebron, Universitat Autonoma Barcelona, Barcelona, Spain
Liver Transpl 8:892-900. 2002.... - Community-based seroepidemiological survey of hepatitis E virus infection in Catalonia, SpainMaria Buti
Liver Service, Vall d'Hebron University Hospital, Barcelona, Spain
Clin Vaccine Immunol 13:1328-32. 2006..68; 95% CI, 1.03 to 2.70). In conclusion, anti-HEV antibodies were detected in 7.3% of the Catalan population. The seroprevalence of anti-HEV antibodies increased with age and was associated with previous minor surgery... - Adherence to Lamivudine after an early withdrawal of hepatitis B immune globulin plays an important role in the long-term prevention of hepatitis B virus recurrenceMaria Buti
Hospital General Valle de Hebrón and CIBER EHD, Barcelona, Spain
Transplantation 84:650-4. 2007..Patients who adhere to long-term prophylaxis with lamivudine after early withdrawal of HBIg have a low risk of HBV recurrence, similar to those who receive combination prophylaxis... - [Patient information. Prophylaxis in hepatitis B virus]M Buti
, Medicina Interna, Hospital General Universitari Vall d'Hebron, Barcelona
Rev Esp Enferm Dig 96:515. 2004 - Risk of acute liver injury associated with the use of drugs: a multicentre population surveyM Sabate
Fundacio Institut Catala de Farmacologia, Universitat Autonoma de Barcelona, Hospital Vall d Hebron, Barcelona, Spain
Aliment Pharmacol Ther 25:1401-9. 2007..Acute liver injury of uncertain aetiology is often drug related and quantitative information about the associated risk is scarce... - Analysis of the evolution in the circulation of HAV and HEV in eastern Spain by testing urban sewage samplesJesus Rodriguez-Manzano
Department of Microbiology, Faculty of Biology, University of Barcelona, Avd Diagonal 645, 08028, Barcelona, Spain
J Water Health 8:346-54. 2010..However, these improvements would not have an equivalent effect on the circulation of HEV and this observation could be explained by the presence of animal reservoirs for HEV, which act as external sources of infections... - Hepatitis E virus epidemiology in industrialized countriesPilar Clemente-Casares
University of Barcelona, Barcelona, Spain
Emerg Infect Dis 9:448-54. 2003..Our results suggest that HEV may be more prevalent than previously considered in industrialized countries and that variants of the virus circulate simultaneously in one region...